Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429949 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
A Phase 2 study of Relapsed, Refractory or Plateau Phase Multiple Myeloma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00429949 is a Phase 2 study of Relapsed, Refractory or Plateau Phase Multiple Myeloma that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00429949, a Phase 2 study of Relapsed, Refractory or Plateau Phase Multiple Myeloma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the response rate (Complete Response \[CR\] and Partial Response \[PR\]) to dasatinib in patients with relapsed, refractory or plateau phase multiple myeloma whose serum paraprotein levels are \>0.5g/dL or urine paraprotein levels are \>1.0g/24 hours.
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (1)
Missouri
- Washington Universtiy in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429949
The ClinicalTrials.gov registry entry for NCT00429949 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed, Refractory or Plateau Phase Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT00429949 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00429949 about?
NCT00429949 is a clinical study titled "A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma". To evaluate the response rate (Complete Response \[CR\] and Partial Response \[PR\]) to dasatinib in patients with relapsed, refractory or plateau phase multiple myeloma whose serum paraprotein levels are \>0.5g/dL or urine paraprotein levels are \>1.0g/24 hours.
What is the current status of trial NCT00429949?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-01. Estimated completion is 2008-01.
What conditions does trial NCT00429949 study?
This clinical trial studies the following conditions: Relapsed, Refractory or Plateau Phase Multiple Myeloma.
What interventions are being tested in trial NCT00429949?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00429949?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00429949 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.